Xtant Medical Holdings (Xtant Medical Holdings) Total Inventories : $36.89 Mil (As of Dec. 2023)

View and export this data going back to 2007. Start your Free Trial

What is Xtant Medical Holdings Total Inventories?

Xtant Medical Holdings's total inventories for the quarter that ended in Dec. 2023 was $36.89 Mil. Xtant Medical Holdings's average total inventories from the quarter that ended in Sep. 2023 to the quarter that ended in Dec. 2023 was $35.61 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Xtant Medical Holdings's Net-Net Working Capital per share for the quarter that ended in Dec. 2023 was $-0.01.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Xtant Medical Holdings's Days Inventory for the three months ended in Dec. 2023 was 296.18.

Inventory Turnover measures how fast the company turns over its inventory within a year. Xtant Medical Holdings's Inventory Turnover for the quarter that ended in Dec. 2023 was 0.31.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Xtant Medical Holdings's Inventory-to-Revenue for the quarter that ended in Dec. 2023 was 1.27.

Xtant Medical Holdings Total Inventories Historical Data

The historical data trend for Xtant Medical Holdings's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xtant Medical Holdings Total Inventories Chart

Xtant Medical Holdings Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Inventories

Get a 7-Day Free Trial

16.10

21.41

17.95

17.29

36.89

Xtant Medical Holdings Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Total Inventories	Get a 7-Day Free Trial															17.29	18.52	20.36	34.33	36.89

Xtant Medical Holdings Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.

Xtant Medical Holdings (AMEX:XTNT) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

Xtant Medical Holdings's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2023 is

	Net-Net Working Capital Per Share (Q: Dec. 2023 )
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(5.715	+	0.75 * 20.731	+	0.5 * 36.885	-	41.263
-	0	-	0)	/	130.18
=	-0.01

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Xtant Medical Holdings's Days Inventory for the three months ended in Dec. 2023 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Dec. 2023 )	/	Cost of Goods Sold (Q: Dec. 2023 )	*	Days in Period
	=	35.6095	/	10.971	*	365 / 4
	=	296.18

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

Xtant Medical Holdings's Inventory Turnover for the quarter that ended in Dec. 2023 is calculated as

Inventory Turnover	=	Cost of Goods Sold (Q: Dec. 2023 )	/	Average Total Inventories (Q: Dec. 2023 )
	=	10.971	/	35.6095
	=	0.31

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Xtant Medical Holdings's Inventory to Revenue for the quarter that ended in Dec. 2023 is calculated as

Inventory-to-Revenue	=	Average Total Inventories (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	35.6095	/	28.108
	=	1.27

Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.

Xtant Medical Holdings Total Inventories Related Terms

Thank you for viewing the detailed overview of Xtant Medical Holdings's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.

Xtant Medical Holdings (Xtant Medical Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Xtant Medical Holdings Inc (AMEX:XTNT) » Definitions » Total Inventories

Comparable Companies

Traded in Other Exchanges

XMS:Germany

Address

664 Cruiser Lane, Belgrade, MT, USA, 59714

Website

http://www.xtantmedical.com

Xtant Medical Holdings Inc is a medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity and degenerative procedures. Its products are used by orthopedic spine surgeons and neurosurgeons to treat a variety of spinal disorders in the cervical, thoracolumbar, and interbody spine. The company's biomaterial products include OsteoSponge, OsteoSponge SC, OsteoSelect DBM putty, OsteoSelect Plus DBM putty, OsteoWrap, and the line of 3Demin products, as well as other allografts. It generates a majority of its revenue from the US.

Executives

Kevin D Brandt	officer: VP & Chief Commercial Officer	11621 RESEARCH CIRCLE, ALACHUA FL 32615
Lori D Mitchell-keller	director	664 CRUISER LANE, BELGRADE MT 59714
Jonn R. Beeson	director	664 CRUISER LANE, BELGRADE MT 59714
Scott C Neils	officer: Interim CFO	664 CRUISER LANE, BELGRADE MT 59714
Mark A. Schallenberger	officer: Chief Operations Officer	664 CRUISER LANE, BELGRADE MT 59714
Sean E Browne	officer: President and CEO	664 CRUISER LANE, BELGRADE MT 59714
Stavros G. Vizirgianakis	director	1/16-18 TENNYSON ST., WILLIAMSTOWN NORTH, VICTORIA CA 3016
Orbimed Rof Ii Llc	director, 10 percent owner	601 LEXINGTON AVE., 54TH FLOOR, NEW YORK NY 10022
Greg Jensen	officer: VP, Finance and Interim CFO	664 CRUISER LANE, BELGRADE MT 59714
Ronald G. Berlin	officer: VP & Chief Operations Officer	664 CRUISER LANE, BELGRADE MT 59714
Kathie J. Lenzen	officer: SVP Fiance & Admin. & CFO	664 CRUISER LANE, BELGRADE MT 59714
Orbimed Advisors Llc	10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Matthew Rizzo	director, 10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Michael Eggenberg	director, 10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Robert Mcnamara	director	C/O LDR HOLDING CORPORATION, 13785 RESEARCH BOULEVARD, SUITE 200, AUSTIN TX 78750